Libero Pharma secures £1.2m for transdermal drug delivery formulations

Transdermal patch formulations for drugs such as Naltrexone are the core focus of Libero Pharma Limited, an Edinburgh-based pharmaceutical manufacturing firm located in the United Kingdom, which recently secured an estimated £1.2m in new funding. The company specializes in the sustained systemic delivery of small-molecule opioid receptor antagonists to treat unmet medical needs within the psychiatric and central nervous system space. These include Opioid Use Disorder, Alcohol Use Disorder, Fibromyalgia, and Crohn's disease.

Incorporated in 2018, the business is classified under other business support service activities n.e.c. and operates the website liberopharma.com. According to its latest financial accounts for the period ending 28 February 2025, the entity recorded a £569.1k loss. A workforce of five employees currently manages operations.

This round represents the only capital raised by the company in 2026, with both the allotment and the formal filing taking place in June.